Amino-01 (July 2018)

Amino-01 (JULY 2018) 180124 AA SPIFAN SLV Appendices A-I

FOR ERP USE ONLY DO NOT DISTRIBUTE

Single Laboratory Validation Report for Total Amino Acids by UHPLC-UV in Infant Formulas and Adult Nutritionals -– APPENDICES (A to I) Appendix H : recovery data obtained with the SPIFAN II SLV kit products, color-coded with respect to performance requirement values.

SPIFAN II SLV kit product

Analyte 1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19

Recovery data were obtained with robust statistics. For each analyte/matrix pair, the recovery was compared with the corresponding performance requirement*. 93% of the values are within the requirements (green) and 7% outside (red). The last column represents the averaged values for each analyte. * updated version proposed by the amino acid working group to be reviewed by the stakeholder panel during the August 2018 annual meeting. His 98.4% 99.9% 98.6% 90.1% 100.1% 92.6% 99.6% 108.9% 94.8% 103.3% 95.1% 102.1% 96.0% 102.5% 97.9% 97.2% 97.7% 98.7% 97.5% Tau 100.3% 101.0% 99.1% 94.0% 96.0% 97.0% 97.0% 97.9% 96.2% 100.0% 95.9% 109.6% 99.7% 99.2% 98.2% 97.9% 99.2% 100.1% 99.4% Ser 109.5% 103.0% 96.6% 91.4% 79.8% 104.0% 93.2% 95.3% 97.5% 95.0% 93.2% 102.1% 93.0% 94.0% 96.8% 96.4% 91.8% 95.6% 99.1% Arg 96.5% 98.3% 101.4% 90.8% 92.4% 94.8% 91.9% 93.1% 93.2% 91.6% 93.8% 104.4% 90.3% 92.6% 94.5% 97.1% 95.7% 99.5% 95.9% Gly 100.2% 99.4% 100.4% 94.3% 98.4% 97.9% 97.5% 97.0% 97.1% 104.4% 97.5% 107.2% 106.2% 102.3% 97.0% 98.2% 101.2% 99.4% 98.6% Asp 112.7% 110.5% 102.8% 101.1% 108.0% 105.2% 104.9% 108.5% 114.1% 107.4% 104.1% 112.1% 108.5% 108.9% 106.6% 103.6% 105.0% 102.3% 105.5% Glu 106.9% 103.5% 105.5% 94.2% 103.6% 103.4% 98.6% 102.1% 110.4% 103.6% 99.6% 109.7% 103.3% 103.8% 101.1% 100.0% 101.3% 98.7% 98.4% Thr 100.0% 99.2% 98.6% 92.0% 90.5% 99.6% 94.8% 95.7% 97.2% 97.2% 94.8% 104.6% 96.8% 97.2% 96.6% 96.7% 96.1% 97.2% 97.7% Ala 102.2% 102.2% 101.7% 95.7% 99.9% 99.5% 98.0% 101.1% 104.2% 101.5% 98.2% 107.6% 102.1% 101.7% 99.9% 98.9% 100.1% 99.7% 99.3% Pro 101.0% 100.5% 103.5% 93.7% 97.4% 100.2% 95.5% 99.1% 101.4% 99.1% 94.3% 106.3% 98.8% 99.5% 98.4% 97.5% 99.0% 99.3% 97.0% Lys 107.7% 106.2% 106.6% 98.9% 100.5% 100.6% 97.3% 105.8% 112.9% 100.5% 97.1% 104.3% 102.5% 101.9% 102.5% 102.1% 104.3% 104.1% 99.6% Tyr 99.9% 99.9% 98.4% 93.9% 92.8% 96.1% 92.6% 94.1% 95.7% 97.9% 93.5% 102.2% 95.7% 97.3% 96.8% 97.2% 96.8% 99.1% 96.9% xCys 102.0% 102.6% 103.3% 94.0% 96.4% 99.4% 96.6% 99.8% 99.7% 101.3% 102.2% 100.6% 98.7% 100.4% 100.8% 99.9% 101.8% 96.1% 97.2% Met 88.7% 90.1% 94.6% 90.2% 89.6% 95.4% 89.8% 88.2% 90.2% 95.8% 90.2% 102.5% 93.9% 94.9% 92.7% 93.6% 92.7% 93.6% 90.8% Val 94.0% 101.2% 100.5% 85.4% 101.5% 91.6% 94.3% 98.4% 100.0% 98.3% 95.3% 107.9% 100.5% 99.3% 98.1% 97.3% 99.8% 102.8% 93.4% Ile 94.2% 101.0% 99.7% 87.0% 101.3% 89.8% 93.8% 97.7% 98.7% 101.2% 96.1% 107.6% 99.9% 99.6% 97.6% 97.5% 99.5% 102.1% 94.8% Leu 100.2% 101.5% 102.2% 91.4% 98.9% 96.8% 95.8% 98.8% 102.0% 99.6% 96.4% 107.9% 101.5% 100.1% 99.0% 98.3% 99.9% 101.6% 95.7% Phe 99.9% 100.8% 100.3% 93.0% 98.4% 96.8% 96.8% 95.9% 96.4% 100.2% 96.4% 108.2% 102.1% 100.0% 98.8% 98.2% 99.4% 100.8% 97.5%

Jaudzems, Guthrie, Lahrichi, and Fuerer – January 2018

page 8/22